- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07515651
Molekylær billeddannende informeret stråledosiseskalering til steder med tilbagevendende sygdom og de-eskalering til ikke-involverede områder i redningsstrålebehandling ved brug af SBRT for prostatakræft for at reducere behandlingstoksicitet (MIDAS-SBRT)
Molekylær billeddannende informeret stråledosiseskalering til steder med tilbagevendende sygdom og de-eskalering til uinvolverede områder i redningsstrålebehandling ved brug af SBRT for prostatakræft for at reducere behandlingstoksicitet
This is a single arm trial that is recruiting a total of 50 participants that have been diagnosed with prostate bed (where the prostate was taken out) or regional (surrounding lymph nodes) recurrence of a prostate cancer following surgery. Salvage radiation treatment represents the main treatment option, with long-term cure rates on the order of 70%. Currently, salvage radiation treatment to the prostate bed and the pelvic lymph nodes is delivered using external beam radiation therapy (EBRT) in 20-33 sessions, over 4-6.5 weeks. Potential study participants have undergone a PSMA PET scan, which has found recurrent cancer in the prostate bed or lymph nodes. This study will investigate personalizing your radiation treatment based on this information. Participants on this study will receive lower than standard radiation dose to areas of the surgical site which do not show evidence of disease on the scan.
This personalized radiotherapy will be delivered in 5 treatments over two weeks, rather than the four to 6 weeks which is the current standard of care. Participants will have a routine history, blood collection for PSA and hormone levels, toxicity assessment, and EPIC-26 & IPSS questionnaires at each follow-up visit. These will take place at 1, 3, 6, 12, 24, 36, and 60 months after radiation treatment.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Andrew McPartlin, MD
- Telefonnummer: 4855 416-946-4501
- E-mail: andrew.mcpartlin@uhn.ca
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network - Princess Margaret Cancer Center
-
Kontakt:
- Andrew McPartlin, MD
- Telefonnummer: 4855 416-946-4501
- E-mail: andrew.mcpartlin@uhn.ca
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years old.
- Histologically proven initial diagnosis of adenocarcinoma prostate cancer.
- Radical prostatectomy > 6 months prior to commencing SBRT.
- Biochemical relapse with local and/or regional recurrence proven with PSMA PET
- ECOG 0-1.
Exclusion Criteria:
- Presence of para-aortic lymph nodes or distant metastasis.
- Chronic pelvic inflammatory disease.
- Contraindication for radiation treatment.
- Previous radiation treatment within the pelvis.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Molecular Imaging Informed Radiation Dose Escalation and De-escalation
Molecular imaging informed radiation dose escalation to sites of recurrent disease and de-escalation to uninvolved areas. |
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Radiation-induced Acute Grade ≥2 Toxicity
Tidsramme: Baseline to 5-year follow up
|
Acute (less than or equal to 90 days) toxicity will be evaluated by using prospective follow-up and grading according to the latest version of the Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
Baseline to 5-year follow up
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Acute and Late GI and GU toxicities
Tidsramme: Estimated at 6 months and 2 years following treatment
|
Cumulative incidence function will be used to estimate the cumulative incidence of grade ≥2 GI and GU, graded per Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
Estimated at 6 months and 2 years following treatment
|
|
Local Recurrence
Tidsramme: Estimated at 2 years and 5 years following treatment
|
Cumulative incidence function with death as a competing risk will be used to estimate local recurrence |
Estimated at 2 years and 5 years following treatment
|
|
Biochemical Disease Free Survival
Tidsramme: Estimated at 2 years and 5 years following treatment
|
Defined as survival until evidence of either biochemical progression (defined as a rise in prostate-specific antigen (PSA) ≥0.2ng/ml above the PSA nadir followed by a sequentially equal or higher value) following postoperative radiotherapy, clinical or radiological progression, initiation of non-protocol systemic therapy, or death from prostate cancer |
Estimated at 2 years and 5 years following treatment
|
|
Patient-reported quality-of-life assessed by EPIC-26 and IPSS
Tidsramme: Baseline to 5-year follow-up
|
Patient-Reported Quality of Life will be assessed at baseline and at each follow-up visit (1, 3, 6, 12, 18, 24, 36, 48, and 60 months) using the following assessment questionnaires: EPIC-26 and IPSS |
Baseline to 5-year follow-up
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Genitale neoplasmer, mandlige
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Kønssygdomme, mandlige
- Prostatasygdomme
- Mandlige urogenitale sygdomme
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Karcinom
- Prostatiske neoplasmer
- Adenocarcinom
- Terapeutik
- Strålebehandling
- Strålebehandling, billedstyret
Andre undersøgelses-id-numre
- 25-6057
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .